Clinical

Cancer Treatment

The Division of Hematology-Oncology is internationally recognized for its leadership in the prevention, detection, diagnosis, and treatment of cancer. The Division maintains a close collaboration with UPMC Hillman Cancer Center (HCC), the region’s only NCI-designated comprehensive cancer center. Together, we are highly committed to meeting the highest standards of cancer care and providing the most advanced treatment of all types of cancers.

Our physicians utilize standardized clinical pathways through web-based decision-support tools to help guide physicians in developing a treatment plan customized for each patient’s particular type and stage of cancer. Each pathway is rooted in scientific evidence and combines innovative and promising clinical trial options with the best standard-of-care therapies. Moreover, HCC is a national leader in immunotherapy research and treatment and the first center in western Pennsylvania to offer chimeric antigen receptor (CAR) T-cell therapy.

We offer patients access to the latest advances in cancer prevention, detection, diagnosis, and treatment through more than 400 active clinical trials. These trials are also available at many of the UPMC Hillman network locations, bringing cutting-edge research and clinical care close to where our patients live. And with faculty engaged in numerous multidisciplinary tumor board clinics and conferences, our clinicians are able to collaborate across oncology disciplines, providing the highest quality patient care. This cooperation also allows many patients with malignancies to see all of their oncology specialists in one day.

Benign Hematology

The Section of Benign Hematology, comprised of more than 10 physician-scientists and research investigators, is of the largest benign hematology programs in the nation with areas of excellence in hemophilia, bleeding disorders, and sickle cell disease. Additional areas of strength include transfusion medicine, inherited and acquired platelet disorders, and rare hematological diseases.

The Section of Benign Hematology clinical research team, named ARCH, includes 5 clinical research staff members and oversees >20 clinical studies, primarily in sickle cell disease, but with a growing number of protocols in other areas of benign hematology, such as acquired platelet disorders and autoimmune hemolytic anemias.